Heartbeam, Inc. (BEATW) — SEC Filings
Heartbeam, Inc. (BEATW) — 21 SEC filings. Latest: 8-K (Nov 21, 2025). Includes 11 8-K, 6 10-Q, 2 DEF 14A.
View Heartbeam, Inc. on SEC EDGAR
Overview
Heartbeam, Inc. (BEATW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: HeartBeam, Inc. reported a net loss of $5.255 million for the three months ended September 30, 2025, a 5.5% increase from the $4.979 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $15.713 million, up from $14.541 million in 2024, re
Sentiment Summary
Across 21 filings, the sentiment breakdown is: 2 bearish, 18 neutral, 1 mixed. The dominant filing sentiment for Heartbeam, Inc. is neutral.
Filing Type Overview
Heartbeam, Inc. (BEATW) has filed 11 8-K, 6 10-Q, 2 DEF 14A, 2 10-K with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (21)
Risk Profile
Risk Assessment: Of BEATW's 19 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$15.713M |
| EPS | -$0.48 |
| Debt-to-Equity | N/A |
| Cash Position | $1.856M |
| Operating Margin | N/A |
| Total Assets | $2.876M |
| Total Debt | N/A |
Key Executives
- Chief Executive Officer
- Richard Ferrari
- Branislav Vajdic
- Robert Eno
- George A. de Urioste
- Marga Ortigas-Wedekind
- Willem Elfrink
- Mark Strome
- Kenneth Nelson
- Dr. Michael J. McGovern
- Ms. Wendy L. Johnson
Industry Context
The medical device industry, particularly in cardiac monitoring, is characterized by rapid technological advancement and stringent regulatory oversight. Companies like HeartBeam are developing innovative solutions for remote patient monitoring and diagnostics. The competitive landscape includes established players and emerging startups, all vying for market share and investor capital. Trends include the increasing adoption of AI and machine learning for data analysis and the growing demand for wearable and patient-friendly devices.
Top Tags
Medical Devices (5) · financials (5) · corporate-governance (4) · 10-Q (4) · quarterly-report (3) · Going Concern (2) · FDA Clearance (2) · Cash Burn (2) · Biotechnology (2) · financial-reporting (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $1.856M | As of September 30, 2025, down from $2.377M at Dec 31, 2024 |
| Net Loss | $5.255M | For three months ended September 30, 2025, up from $4.979M in 2024 |
| Available under ATM sales agreement | $15.5M | As of financial statement issuance date, for future equity sales |
| Proceeds from sale of equity | $10.250M | Net of issuance costs, for nine months ended September 30, 2025 |
| Common shares outstanding | 34,443,563 | As of November 11, 2025 |
| Common shares issued and outstanding | 34,340,727 | As of September 30, 2025, up from 26,960,901 at Dec 31, 2024 |
| Total operating expenses | $5,290 | For three months ended September 30, 2025, up from $5,069 in 2024 |
| Research and development expenses | $3,278 | For three months ended September 30, 2025, up from $2,893 in 2024 |
| Net cash used in operating activities | $11,082 | For nine months ended September 30, 2025, up from $10,319 in 2024 |
| Cash & Short-term Investments | $5.1M | As of June 30, 2025, deemed insufficient for next 12 months |
| Research and Development Expenses | $6.818M | Increased from $5.272M for the six months ended June 30, 2024 |
| Net Cash from Financing | $10.700M | Primary source of liquidity for the six months ended June 30, 2025 |
| ATM Availability | $15.6M | Remaining capital available under At-the-Market sales agreement |
| Common Shares Outstanding | 34,020,340 | As of June 30, 2025, up from 26,960,901 at Dec 31, 2024, indicating dilution |
| Net Cash Used in Operating Activities | $7.922M | For the six months ended June 30, 2025, up from $7.013M in 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Heartbeam, Inc. (BEATW)?
Heartbeam, Inc. has 21 recent SEC filings from Feb 2024 to Nov 2025, including 11 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BEATW filings?
Across 21 filings, the sentiment breakdown is: 2 bearish, 18 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Heartbeam, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Heartbeam, Inc. (BEATW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Heartbeam, Inc.?
Key financial highlights from Heartbeam, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BEATW?
The investment thesis for BEATW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Heartbeam, Inc.?
Key executives identified across Heartbeam, Inc.'s filings include Chief Executive Officer, Richard Ferrari, Branislav Vajdic, Robert Eno, George A. de Urioste and 6 others.
What are the main risk factors for Heartbeam, Inc. stock?
Of BEATW's 19 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Heartbeam, Inc.?
Forward guidance and predictions for Heartbeam, Inc. are extracted from SEC filings as they are enriched.